Quick Facts: Main Uses

• May help manage the symptoms associated with seasonal allergic conjunctivitis.
• Contributes to the alleviation of ocular discomfort and irritation.

---

Reactine, which contains the active ingredient levocabastine, is a medication used for the symptomatic management of seasonal allergic conjunctivitis. This condition involves the eyes' reaction to allergens such as pollen, which may cause inflammation and irritation.

Levocabastine can contribute to the alleviation of key symptoms associated with allergic eye conditions. These symptoms include itching of the eyes, redness, watering, and tearing. This medication is indicated for use in the eyes to provide temporary relief of these discomforts. The treatment is intended to address the effects of the allergic reaction in the conjunctiva.

This section outlines the official eligibility and exclusion criteria for levocabastine, strictly based on authoritative government regulatory documents.

Eligibility and Exclusion Criteria

The primary absolute contraindication is a known or suspected hypersensitivity or allergy to levocabastine or any of the product's inactive components. Individuals with this condition must not use the medication.

Population Group	Eligibility Status (Official Classification)
Hypersensitivity to Components	Contraindicated
Children (Ophthalmic)	Safety and effectiveness not established below the age of 12 years (US label)
Soft Contact Lens Wearers	Restricted (Must remove lenses before application)
Pregnancy	Restricted (Category C); Use only if potential benefit justifies risk to fetus
Lactation/Nursing Mothers	Caution recommended; minute amounts are detected in human breast milk
Renal Impairment	Caution recommended; use with physician guidance due to renal excretion

Official labeling has not established the safety and effectiveness for pediatric patients below the age of 12 for the ophthalmic suspension. For all patients, particularly pregnant women and those with renal impairment, use is restricted and requires careful consideration by a healthcare professional. The eye drop formulation is also contraindicated for use while soft contact lenses are being worn due to a preservative in the suspension.

Interactions with other medicines and products

Official regulatory information for Levocabastine is defined by its topical application, resulting in minimal systemic exposure and low interaction risk with most systemically administered medicines. The drug's interaction profile is structured by specific pharmacokinetic studies and population-dependent considerations as documented in product labels.

Documented Pharmacokinetic Findings

Co-administration with the topical nasal decongestant Oxymetazoline may cause a transient reduction in the absorption of intranasal Levocabastine. Formal studies documented that known CYP3A4 inhibitors such as Ketoconazole and Erythromycin have no impact on the pharmacokinetics of intranasal Levocabastine. Furthermore, Levocabastine did not alter the pharmacokinetics of the antihistamine Loratadine.

Pharmacodynamic and Substance Interactions

Official documents state there is no evidence of potentiation when Levocabastine nasal spray is used alongside central nervous system depressants, including Diazepam or alcohol. No specific interactions with food, supplements, or herbal products are documented in official prescribing information.

Population-Specific Caution

Patients with moderate to severe renal impairment represent a specific risk population due to Levocabastine’s reliance on renal clearance. In this population, systemic exposure (AUC) is officially noted to be increased by 56%, with a significant prolongation of the elimination half-life.

Targeting the Histamine Signaling Pathway

The drug's primary action is highly specific: it is a selective H1 receptor antagonist that competitively binds to H1 receptors on various effector cells. This mechanism directly blocks the activation signal from the naturally released mediator, histamine, thereby interrupting the initial molecular steps of the histamine-mediated cascade.

---

Controlling Local Tissue Fluid Dynamics

By preventing H1 receptor activation, the mechanism interrupts the signals that normally cause small blood vessels to widen and become permeable. This leads to the reduction of histamine-induced vascular permeability, a physiological consequence that results in less leakage of plasma and other substances from the blood into the surrounding tissues, maintaining the structural integrity of the local microvasculature.

---

Peripheral and Highly Focused Modulation

The drug's activity is characterized by a predominantly peripheral mechanism of action, meaning its molecular interaction is centered on the tissues where the drug is applied (e.g., the eyes or nose). This targeted engagement supports the regulation of overactive peripheral processes by achieving a high concentration of the antagonist at the affected H1 receptors without significant systemic distribution, allowing for targeted pathway modulation.

How to Use Levocabastine (Reactine/Livostin)

Levocabastine is an antihistamine administered topically as either an ophthalmic (eye drop) or nasal (nasal spray) suspension. Adherence to provided instructions is essential for proper use.

Administration and Dosage

Administration Route	Standard Starting Dose	Maximum Frequency
Ophthalmic (Eye Drops)	1 drop in each affected eye	Up to 4 times daily
Nasal (Nasal Spray)	2 sprays in each nostril	Up to 4 times daily

For both formulations, the bottle must be shaken well before each use to ensure the suspension is properly mixed. The dosing applies to adults and children 6 years of age and older.

Procedural Steps

Nasal Spray: Before initial use, the spray pump must be primed by depressing it until a fine mist appears. Clear the nostrils by gently blowing the nose. Insert the nozzle into one nostril and administer two sprays while gently inhaling through the nose. Repeat the process in the other nostril.

Eye Drops: Do not allow the dropper tip to touch the eye or any surface. After instillation, close the eye gently without blinking or rubbing, and apply light pressure to the corner of the eye near the nose for a few minutes to limit systemic absorption.

Missed Dose and Duration

If a dose is missed, administer it as soon as it is remembered. If it is almost time for the next scheduled dose, skip the missed dose, and return to the regular schedule; do not double the dose. The duration of continuous use may be limited to 8 to 10 weeks.

Research evidence / Overview of studies for Reactine (Levocabastine)

---

Evidence for Use in Seasonal Allergic Conjunctivitis

Research for levocabastine eye drops has involved short-term studies, including Randomized Controlled Trials (RCTs) and specialized allergen challenge models. These studies are designed to explore how symptoms, linked to inflammatory or irritative states, change over defined time periods. Researchers monitored patient-reported outcomes describing perceived discomfort, focusing on outcomes related to physical discomfort such as the intensity of eye itching, redness, and the presence of tearing. Findings from these trials describe patterns observed in the studies, which included measurements of short-term or episodic symptom patterns linked to inflammatory or irritative states. Results apply only to the populations studied, and certainty remains low for outcomes beyond this short period.

---

Evidence for Use in Allergic Rhinitis

Research examining the levocabastine nasal spray was evaluated in studies focusing on conditions characterized by fluctuating or episodic manifestations, specifically allergic rhinitis. Among the outcomes related to physical discomfort that research examined were specific nasal symptoms, including measuring the intensity and variability of symptoms such as sneezing, runny nose (rhinorrhea), nasal itching, and nasal congestion. Data relate to patterns observed in these patient-reported outcomes describing perceived discomfort when comparing the levocabastine group to the control group. Research describes that for certain outcomes, such as measurements related to nasal congestion, findings were mixed or the observed measurements varied more significantly across studies than for other symptoms.

---

Durability of Relief and Long-Term Follow-up Studies

Research exploring how symptoms change over time has examined the initial response following the application of levocabastine. Studies conducted during periods of increased symptom activity have monitored how quickly relief was observed. Regarding the duration of effect, research has explored the persistence of short-term symptom patterns in acute settings. However, there is limited information for long-term outcomes. Long-term effects are not fully established because the follow-up durations were limited in the primary research.

---

Research Gaps and What Remains Uncertain

Most notably, there is limited information for long-term outcomes and how symptom patterns change over multiple months or years of intermittent use. The existing evidence primarily focuses on acute or short-term seasonal management. Furthermore, data for certain groups remain insufficient, particularly for patients with certain pre-existing medical conditions. Research provides context but not individual predictions, highlighting what is known—and what is still uncertain—about levocabastine’s performance across all potential users.

Key Studies & References

1. Evaluation of the new ophthalmic antihistamine, 0.05% levocabastine, in the clinical allergen challenge model of allergic conjunctivitis
2. Label: livostin- levocabastine hydrochloride suspension (U.S. Food and Drug Administration Regulatory Summary)

Common questions about Reactine (Levocabastine) (FAQ)

Q: How quickly does Levocabastine start working for eye or nasal allergy symptoms?

A: Official product information indicates that Levocabastine is a fast-acting medication. Following its application to the eyes or nose, relief from typical allergic symptoms is generally observed quickly after administration. The effect is designed to be sustained for several hours.

Q: How do I properly dispose of expired Levocabastine?

A: Regulatory guidance for disposal suggests removing the medicine from its original container and mixing it with an undesirable substance, such as used coffee grounds or kitty litter. This is done to prevent accidental ingestion. This mixture is then typically placed into a sealable bag or container before being thrown into the household trash.

Q: Can children under 6 years old use Levocabastine?

A: According to the official product information, the dosing instructions for the nasal spray are established for children aged 6 years and older. For the eye drop formulation, some regulatory bodies state that the safety and effectiveness have not been established for children younger than 12 years. Decisions regarding the use of this medication in children should be made in consultation with a healthcare professional.

Q: What are the symptoms Levocabastine is used to treat?

A: Levocabastine is specifically indicated for treating symptoms associated with allergic reactions. For the eye drops, this includes relief from watery, itchy, red eyes, and swollen eyelids. The nasal spray is used to relieve common nasal allergy symptoms such as sneezing, a runny nose (rhinorrhea), and nasal irritation.

Q: Do I need a prescription to buy Levocabastine (Reactine/Livostin)?

A: The required legal status for purchasing Levocabastine can vary by country or region. In certain markets, the drug is available for purchase without a prescription (over-the-counter or OTC). However, in other regions, such as the United States, the ophthalmic (eye drop) form is designated as a prescription-only (Rx-only) medicine.

Q: Is Levocabastine known by any other brand names?

A: Yes, Levocabastine is the active pharmaceutical ingredient itself. This compound is marketed globally under several different brand names, including Livostin. In some contexts, the brand name Reactine may also be associated with this specific active ingredient.

Q: How is Levocabastine eliminated from the body?

A: According to official drug labels, Levocabastine is predominantly cleared from the body by the kidneys. Approximately 70% of the drug’s active substance is recovered unchanged in the urine, indicating that the renal system is the main pathway for its elimination.

Q: Can I use Levocabastine to treat non-allergic symptoms like a common cold?

A: Official product indications specify that Levocabastine is for the treatment of symptoms related to allergic conditions. The medication is specifically indicated for allergic conditions and is not intended for non-allergic symptoms like those associated with a common cold.

Q: Can I use other eye drops or nasal sprays at the same time as Levocabastine?

A: The official product information notes a specific pharmacokinetic finding: co-administering the nasal spray with the topical nasal decongestant Oxymetazoline may reduce the drug’s absorption. Generally, individuals are advised to inform a healthcare professional about all other topical or systemic medicines they are using to prevent potential interactions.

Official Storage and Disposal Instructions for Levocabastine

Levocabastine must be stored according to strict regulatory conditions to maintain its quality and efficacy. The medication requires storage at controlled room temperature, generally defined as between 15 C and 30 C (59 F to 86 F). It is mandatory to protect the product from freezing and excessive heat or dampness.

The container must be kept tightly closed when not in use. For the ophthalmic suspension, the product must be discarded one month after opening to comply with stability rules. The medicine must always be stored out of the reach and sight of children.

Expired or unused levocabastine should be disposed of through a dedicated drug take-back program. If this is not an option, the medicine should be mixed with an undesirable substance, sealed in a container, and placed in the household trash. Medications should not be disposed of in wastewater.